BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2007

View Archived Issues

CHF-1512 effective in fluctuating Parkinson's disease

Read More

Recent patents disclose novel antidiabetic agents

Read More

Sirion raises financing to advance pipeline

Read More

New agents for treating Alzheimer's disease imparted in recent Pfizer patent

Read More

WAY-258131, a novel BACE-1 inhibitor with in vivo activity in mouse models of Alzheimer's disease

Read More

Studies support use of doripenem in urinary tract, intra-abdominal infections

Read More

PZ-601 pharmacokinetics assessed in healthy male volunteers

Read More

Hepatitis B surface antigen/1018-ISS combination shows promise

Read More

Selective beta3-adrenoceptor agonists with reduced cardiac side effects reported by Lilly

Read More

Endo receives notices from Anesiva regarding Zingo

Read More

AEE-788 inhibits human hepatocellular carcinoma in vitro and in vivo

Read More

Ditropan to be reviewed by FDA

Read More

sanofi-aventis reports novel therapeutic agents for renal disorders

Read More

FDA Arthritis Advisory Committee meets to discuss Arcoxia

Read More

Cryptopharma selects CP-92 for development in cystic fibrosis

Read More

Repligen licenses Friedreich's ataxia compounds from Scripps Institute

Read More

Xyotax has fast track designation for PS2 women with advanced NSCLC

Read More

Extended release formulation of the 5-HT1A antagonist AV-965 well tolerated in phase I trials

Read More

Rigel updates R-788 program

Read More

FDA extends review for eprodisate NDA

Read More

Pro-Pharmaceuticals receives FDA letter regarding Davanat/5-FU NDA

Read More

ADX-48621 begins phase I for depression, anxiety disorder and pain

Read More

New phase IIb study of pafuramidine maleate for malaria

Read More

Preliminary phase IIa findings for IPL-455903

Read More

Lpath closes first tranche of equity financing

Read More

EGIS-1150 effectively controls positive and negative schizophrenia symptoms in vivo

Read More

New data indicate higher virologic response with celgosivir combination therapy

Read More

Altabax approved for topical treatment of impetigo

Read More

Eisai withdraws European application for Aricept in severe Alzheimer's disease

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing